Sfeir MM - Search Results

1

Antimicrobial Activity of Tebipenem and Comparators against Enterobacterales from diverse Outpatient Centers and Nursing Homes in the United States.

Asempa TE, Bobenchik AM, Bourassa L, Clark AE, Hatch MT, Huse HK, Martin IW, Mochon AB, Munson E, Sfeir MM, Srodon M, Wang Y, Nicolau DP. Asempa TE, et al. Among authors: sfeir mm. Int J Antimicrob Agents. 2023 Mar;61(3):106733. doi: 10.1016/j.ijantimicag.2023.106733. Epub 2023 Jan 20. Int J Antimicrob Agents. 2023. PMID: 36690122

2

Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.

Sfeir MM, Askin G, Christos P. Sfeir MM, et al. Int J Antimicrob Agents. 2018 Nov;52(5):554-570. doi: 10.1016/j.ijantimicag.2018.07.021. Epub 2018 Aug 3. Int J Antimicrob Agents. 2018. PMID: 30081138

3

Antimicrobial Susceptibility Testing for Glucose-Nonfermenting Gram-Negative Bacteria: the Tip of the Iceberg.

Sfeir MM. Sfeir MM. Antimicrob Agents Chemother. 2020 Mar 24;64(4):e00011-20. doi: 10.1128/AAC.00011-20. Print 2020 Mar 24. Antimicrob Agents Chemother. 2020. PMID: 32209566 Free PMC article. No abstract available.

4

Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening: Clinical Use for Excluding Diabetic Foot Infection with MRSA.

Sfeir MM. Sfeir MM. Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00635-20. doi: 10.1128/AAC.00635-20. Print 2020 Jun 23. Antimicrob Agents Chemother. 2020. PMID: 32393485 Free PMC article. No abstract available.

5

Cost-effectiveness of ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae bacteremia and pneumonia.

Simon MS, Sfeir MM, Calfee DP, Satlin MJ. Simon MS, et al. Among authors: sfeir mm. Antimicrob Agents Chemother. 2019 Sep 9;63(12):e00897-19. doi: 10.1128/AAC.00897-19. Epub 2019 Sep 23. Antimicrob Agents Chemother. 2019. PMID: 31548187 Free PMC article.

6

Post-MERINO trial: Any role for piperacillin-tazobactam in treating bloodstream infections caused by extended-spectrum beta-lactamase producing Enterobacteriaceae?

Sfeir MM. Sfeir MM. Int J Antimicrob Agents. 2019 May;53(5):557-558. doi: 10.1016/j.ijantimicag.2019.03.007. Epub 2019 Mar 14. Int J Antimicrob Agents. 2019. PMID: 30880227 No abstract available.

7

Diagnosis of Multidrug-Resistant Pathogens of Pneumonia.

Sfeir MM. Sfeir MM. Diagnostics (Basel). 2021 Dec 7;11(12):2287. doi: 10.3390/diagnostics11122287. Diagnostics (Basel). 2021. PMID: 34943524 Free PMC article. Review.

8

Tigecycline for treatment of multidrug-resistant gram-negative bacteria in transplant recipient patients: Challenges of antimicrobial susceptibility testing.

Sfeir MM. Sfeir MM. Transpl Infect Dis. 2020 Apr;22(2):e13254. doi: 10.1111/tid.13254. Epub 2020 Feb 16. Transpl Infect Dis. 2020. PMID: 32017304 No abstract available.

9

Imipenem-relebactam for Treatment of Carbapenem-resistant Gram-negative Bacteria: Where Do We Stand on In Vitro Susceptibility Testing?

Sfeir MM. Sfeir MM. Clin Infect Dis. 2021 Apr 26;72(8):1484-1485. doi: 10.1093/cid/ciaa878. Clin Infect Dis. 2021. PMID: 32634243 No abstract available.

10

Serologic Testing for Hepatitis B.

Sfeir MM, Snayd M. Sfeir MM, et al. JAMA. 2021 Dec 21;326(23):2423-2424. doi: 10.1001/jama.2021.19803. JAMA. 2021. PMID: 34797375 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page